NEW YORK (GenomeWeb) – Two commercially available sequencing platforms are capable of producing drug-resistance profiles for Mycobacterium tuberculosis, according to a new Genome Medicine study.

There has been a rise in recent years in the incidence of multidrug-resistant and extensively drug-resistant tuberculosis, but gauging the resistance profile of M. tuberculosis can be a slow and expensive process.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.